Paper Details

  1. Home
  2. Paper Details

Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.

Author: FörtigP, KienleE, LübbenG, RegidorM, RegidorP A, RuweB, SchindlerA E, SchmidtM

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the effectiveness of leuprorelin acetate depot (LAD), a GnRH agonist, and lynestrenol (LYN), a progestin, in treating severe endometriosis in 48 women. Both treatments significantly reduced the severity of endometriosis, but LAD was more effective than LYN in reducing symptoms and lowering estrogen levels. While both treatments were well-tolerated, the study recommends GnRH agonists as the first-line treatment for endometriosis, with progestins potentially used for long-term management after GnRH treatment is completed.
Paper Details　
Original Abstract of the Article :
Endometriosis is thought to be an ovarian-dependent benign disease that affects up to 12% of women during their reproductive life. For the past ten years the gonadotropin-releasing hormone (GnRH)-agonists have been proved effective and safe drugs in the treatment of endometriosis. Nevertheless, gest...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/11447732

データ提供：米国国立医学図書館（NLM）

Endometriosis: A Comparative Study of GnRH-agonist and Gestagen

Endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus, is a common challenge for women, affecting up to 12% during their reproductive years. This research explores the effectiveness of two different types of hormonal treatments for endometriosis: GnRH-agonists and gestagens. The study compared the efficacy of leuprorelin acetate, a GnRH-agonist, with lynestrenol, a gestagen, in women with severe endometriosis.

GnRH-agonist: A More Effective Oasis in the Endometriosis Desert

The study found that leuprorelin acetate was significantly more effective than lynestrenol in reducing the severity of endometriosis. After six months of treatment, women receiving leuprorelin acetate experienced a much greater reduction in the size and spread of endometriosis tissue compared to those receiving lynestrenol. This suggests that GnRH-agonists could be the preferred treatment option for endometriosis, especially in cases of severe disease.

Finding the Right Path: Personalized Treatment for Endometriosis

This study highlights the importance of personalized treatment for endometriosis. While GnRH-agonists appear to be more effective in the short term, gestagens may be more suitable for long-term management. It is crucial to consult with a healthcare professional to determine the most appropriate treatment approach based on individual needs and preferences.

Dr.Camel's Conclusion

This study provides valuable insights into the treatment of endometriosis. It suggests that GnRH-agonists are a promising option for effectively managing this condition, particularly in severe cases. However, the choice of treatment should be tailored to individual needs and preferences, taking into account both short-term and long-term goals. This research, like a well-charted path through a vast desert, helps us navigate the complex world of endometriosis and make informed decisions about treatment options.

Date :
  1. Date Completed 2001-12-05
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

11447732

DOI: Digital Object Identifier

11447732

Related Literature

Article Analysis
・Effective treatment of endometriosis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.